Arrowhead Pharmaceuticals, Inc. (ARWR) Monday announced positive topline results from Part 2 of a Phase 1/2 study of ARO-C3 in patients with IgA nephropathy (IgAN).
ARO-C3 is designed to reduce hepatocyte production of complement component 3 (C3) as a potential treatment for various complement mediated renal diseases.
In Part 2 of the Phase 1/2 study, adult patients with C3 Glomerulopathy (C3G) and IgA Nephropathy (IgAN) received 3 doses of ARO-C3. Maximum mean reduction in C3 of 89 percent and mean sustained reduction of greater than 87 percent through week 24 in patients treated with ARO-C3 were observed. Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41 was achieved by week 24.
For comments and feedback: editorial@rttnews.com